MetaCap

Arbutus Biopharma (ABUS) vs Kura Oncology (KURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arbutus Biopharma (ABUS) has outperformed Kura Oncology (KURA) over the past year, losing 6.7% versus a loss of 38.1%. Over five years, ABUS leads with a +28.4% price change compared with -50.7% for KURA. Kura Oncology is the larger company by market cap ($634.9 million vs $616.2 million), about 1.0 times the size, while Arbutus Biopharma is growing revenue faster (+128.2% vs +25.2%).

Arbutus Biopharma converts more of its revenue into profit, with a net margin of -237.9% versus -412.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABUS-6.73%KURA-38.14%
+25%-9%-42%
Nov 21, 20251 yearNov 20, 2026
ABUS+21.82%KURA-59.33%
+64%-5%-74%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABUS versus KURA key metrics
MetricABUSKURA
Share price$4.02$6.91
Market cap$616.24M$634.88M
1-day change-1.23%-5.99%
YTD return-16.42%-33.49%
1-year return-6.73%-38.14%
5-year return+28.43%-50.66%
P/E ratio (TTM)3.59—
EPS (TTM)$1.12$-3.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.08M$67.48M
Revenue growth (YoY)+128.21%+25.24%
Net income (latest FY)$-33.50M$-278.67M
Operating margin-270.96%-449.94%
Net margin-237.88%-412.95%
52-week high$5.45$13.90
52-week low$3.50$6.75
Distance from 52-week high-26.24%-50.29%
Analyst consensusnonestrong_buy
Avg. price target upside+32.34%+357.60%
Average volume4.98M2.10M
Shares outstanding153.29M91.88M
Employees19260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABUS has outperformed KURA by 31.4 percentage points over the past year.
  • Arbutus Biopharma is more profitable, keeping -237.9 cents of every revenue dollar as net income versus -412.9 cents for Kura Oncology.
  • Arbutus Biopharma grew revenue faster in its latest fiscal year (+128.21% vs +25.24%).

About Arbutus Biopharma

ABUS stock →

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Kura Oncology

KURA stock →

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

ABUS vs KURA FAQ

Which is bigger, Arbutus Biopharma or Kura Oncology?

Kura Oncology (KURA) is larger, with a market capitalization of $634.88M compared with $616.24M for Arbutus Biopharma (ABUS).

Which stock has performed better over the past year, ABUS or KURA?

ABUS returned -6.73% over the past 12 months, compared with -38.14% for KURA (price return, excluding dividends). Past performance does not predict future results.

Are Arbutus Biopharma and Kura Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons